PROCEPT BioRobotics Co. (NASDAQ:PRCT) EVP Hisham Shiblaq Sells 247 Shares

PROCEPT BioRobotics Co. (NASDAQ:PRCT) EVP Hisham Shiblaq sold 247 shares of the business’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $14,093.82. Following the completion of the transaction, the executive vice president now owns 63,133 shares in the company, valued at approximately $3,602,368.98. The trade was a 0.39 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

PROCEPT BioRobotics Price Performance

Shares of NASDAQ PRCT opened at $57.80 on Thursday. PROCEPT BioRobotics Co. has a fifty-two week low of $45.56 and a fifty-two week high of $103.81. The stock has a market cap of $3.17 billion, a price-to-earnings ratio of -29.64 and a beta of 1.05. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. The firm’s 50-day simple moving average is $68.87 and its 200 day simple moving average is $78.75.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The company had revenue of $68.24 million for the quarter, compared to analysts’ expectations of $66.79 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. As a group, research analysts anticipate that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PRCT. Raleigh Capital Management Inc. purchased a new position in PROCEPT BioRobotics in the 4th quarter worth $32,000. Thematics Asset Management purchased a new position in shares of PROCEPT BioRobotics in the fourth quarter valued at about $46,000. Signaturefd LLC increased its position in shares of PROCEPT BioRobotics by 26.7% during the fourth quarter. Signaturefd LLC now owns 689 shares of the company’s stock valued at $55,000 after buying an additional 145 shares during the period. IFP Advisors Inc purchased a new position in shares of PROCEPT BioRobotics during the fourth quarter valued at about $58,000. Finally, Arcadia Investment Management Corp MI purchased a new position in shares of PROCEPT BioRobotics during the fourth quarter valued at about $64,000. 89.46% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have commented on the stock. Morgan Stanley cut their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Truist Financial reaffirmed a “buy” rating and set a $90.00 price target (down previously from $105.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, February 26th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating and set a $112.00 price target on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $94.29.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).